RHB-106 is a proprietary oral bowel preparation for GI tract procedures and surgeries. RHB-106 was acquired from Sydney-based Giaconda [ASX: GIA] in August 2010. RHB-106, a tasteless formulated capsule containing electrolytes, targets the indication of oral bowel preparation for GI tract procedures and surgeries. It avoids patient exposure to the often unacceptable taste of current products and allows for an unobstructed procedure with reduced side effects and improved compliance. Phase IIa has been completed with significantly improved patient response and equal bowel cleansing and RedHill is currently executing its development plan.
Latest News
-
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting) -
February 7th, 2012
RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) -
February 2nd, 2012
Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) -
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
See More News